{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:23:11Z","timestamp":1790785391149,"version":"4.1.0"},"reference-count":54,"publisher":"IMR Press","issue":"4","license":[{"start":{"date-parts":[[2023,6,30]],"date-time":"2023-06-30T00:00:00Z","timestamp":1688083200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Zhejiang Medicine and Health Science and Technology Project","award":["2020KY848"],"award-info":[{"award-number":["2020KY848"]}]},{"name":"Project of NINGBO Leading Medical & Health Discipline","award":["2022-B12"],"award-info":[{"award-number":["2022-B12"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J. Integr. Neurosci."],"abstract":"<jats:p>Background: Plasma neurofilament light (NfL) is an intermediate filamentous protein involved in stabilizing axonal structure and promoting axon growth. Recent clinical studies have reported increased NfL levels in the plasma of Alzheimer\u2019s disease (AD) patients and patients with mild cognitive impairment (MCI). This study used meta-analysis to evaluate the potential of plasma NfL as a biomarker for patients with AD and MCI. Methods: PubMed, Embase, and Web of Science databases were systematically searched for studies of plasma NfL levels in AD and MCI, and a meta-analysis was employed to identify whether it was suited as a reliable biomarker and discrimination of healthy controls. Results: A total of 24 published articles that included 2397 AD and 3242 MCI patients were analysed. The level of plasma NfL was significantly increased in patients with AD and MCI when compared with healthy control subjects (standard mean difference [SMD]: 14.33 [12.42\u201316.24], z = 14.71, p &lt; 0.00001; SMD: 4.95 [3.82\u20136.80], z = 8.59, p &lt; 0.00001) and higher in AD patients than MCI patients (SMD: 9.32 [8.07\u201310.57], z = 14.62, p &lt; 0.00001). Meta-regression analysis showed a negative relationship between Mini-Mental State Examination (MMSE) scores and plasma NfL levels in MCI patients (slope = \u20130.399 [95% confidence interval (CI): \u20130.518 to \u20130.281], p &lt; 0.05). Conclusions: The meta-analysis suggested that NfL levels increased in the plasma of patients with AD and MCI and were associated with cognitive decline. Results provide the clinical evidence to support plasma NfL as a cognitive biomarker for AD and MCI.<\/jats:p>","DOI":"10.31083\/j.jin2204085","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T04:48:52Z","timestamp":1688705332000},"source":"Crossref","is-referenced-by-count":30,"title":["Neurofilament Light Chain as a Potential Biomarker in Plasma for Alzheimer's Disease and Mild Cognitive Impairment: A Systematic Review and a Meta-Analysis"],"prefix":"10.31083","volume":"22","author":[{"given":"Zhenyi","family":"Fan","sequence":"first","affiliation":[{"name":"Department of Neurology, Ningbo NO.2 Hospital, 315000 Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Neurology, Ningbo NO.2 Hospital, 315000 Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Geriatrics, Ningbo NO.2 Hospital, 315000 Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caijing","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Geriatrics, Ningbo NO.2 Hospital, 315000 Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhou","sequence":"first","affiliation":[{"name":"Department of Neurology, Ningbo NO.2 Hospital, 315000 Ningbo, Zhejiang, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2023,6,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s Association. 2022 Alzheimer\u2019s disease facts and figures. Alzheimer\u2019s & Dementia. 2022; 18: 700\u2013789.","DOI":"10.1002\/alz.12638"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Querfurth HW, LaFerla FM. Alzheimer\u2019s disease. The New England Journal of Medicine. 2010; 362: 329\u2013344.","DOI":"10.1056\/NEJMra0909142"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Roberts R, Knopman DS. Classification and epidemiology of MCI. Clinics in Geriatric Medicine. 2013; 29: 753\u2013772.","DOI":"10.1016\/j.cger.2013.07.003"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2001; 56: 1133\u20131142.","DOI":"10.1212\/WNL.56.9.1133"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, et al. Alzheimer\u2019s disease. Lancet. 2016; 388: 505\u2013517.","DOI":"10.1016\/S0140-6736(15)01124-1"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Vaz M, Silvestre S. Alzheimer\u2019s disease: Recent treatment strategies. European Journal of Pharmacology. 2020; 887: 173554.","DOI":"10.1016\/j.ejphar.2020.173554"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Gaetani L, Blennow K, Calabresi P, Di Filippo M, Parnetti L, Zetterberg H. Neurofilament light chain as a biomarker in neurological disorders. Journal of Neurology, Neurosurgery, and Psychiatry. 2019; 90: 870\u2013881.","DOI":"10.1136\/jnnp-2018-320106"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Puentes F, Lombardi V, Lu C, Yildiz O, Fratta P, Isaacs A, et al. Humoral response to neurofilaments and dipeptide repeats in ALS progression. Annals of Clinical and Translational Neurology. 2021; 8: 1831\u20131844.","DOI":"10.1002\/acn3.51428"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Yuan A, Rao MV, Veeranna, Nixon RA. Neurofilaments and Neurofilament Proteins in Health and Disease. Cold Spring Harbor Perspectives in Biology. 2017; 9: a018309.","DOI":"10.1101\/cshperspect.a018309"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"van Lieverloo GGA, Wieske L, Verhamme C, Vrancken AFJ, van Doorn PA, Michalak Z, et al. Serum neurofilament light chain in chronic inflammatory demyelinating polyneuropathy. Journal of the Peripheral Nervous System. 2019; 24: 187\u2013194.","DOI":"10.1111\/jns.12319"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J, et al. Current state of Alzheimer\u2019s fluid biomarkers. Acta Neuropathologica. 2018; 136: 821\u2013853.","DOI":"10.1007\/s00401-018-1932-x"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Barro C, Chitnis T, Weiner HL. Blood neurofilament light: a critical review of its application to neurologic disease. Annals of Clinical and Translational Neurology. 2020; 7: 2508\u20132523.","DOI":"10.1002\/acn3.51234"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of Internal Medicine. 2009; 151: 264\u2013269.","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, et al. Research criteria for the diagnosis of Alzheimer\u2019s disease: revising the NINCDS-ADRDA criteria. The Lancet Neurology. 2007; 6: 734\u2013746.","DOI":"10.1016\/S1474-4422(07)70178-3"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Albert MS, DeKosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, et al. The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia. 2011; 7: 270\u2013279.","DOI":"10.1016\/j.jalz.2011.03.008"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Archives of Neurology. 1999; 56: 303\u2013308.","DOI":"10.1001\/archneur.56.3.303"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Lo CK, Mertz D, Loeb M. Newcastle-Ottawa Scale: comparing reviewers\u2019 to authors\u2019 assessments. BMC Medical Research Methodology. 2014; 14: 45.","DOI":"10.1186\/1471-2288-14-45"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Medical Research Methodology. 2014; 14: 135.","DOI":"10.1186\/1471-2288-14-135"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Luo D, Wan X, Liu J, Tong T. Optimally estimating the sample mean from the sample size, median, mid-range, and\/or mid-quartile range. Statistical Methods in Medical Research. 2018; 27: 1785\u20131805.","DOI":"10.1177\/0962280216669183"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Andersson E, Janelidze S, Lampinen B, Nilsson M, Leuzy A, Stomrud E, et al. Blood and cerebrospinal fluid neurofilament light differentially detect neurodegeneration in early Alzheimer\u2019s disease. Neurobiology of Aging. 2020; 95: 143\u2013153.","DOI":"10.1016\/j.neurobiolaging.2020.07.018"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Barker W, Quinonez C, Greig MT, Behar R, Chirinos C, Rodriguez RA, et al. Utility of Plasma Neurofilament Light in the 1Florida Alzheimer\u2019s Disease Research Center (ADRC). Journal of Alzheimer\u2019s Disease. 2021; 79: 59\u201370.","DOI":"10.3233\/JAD-200901"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Brickman AM, Manly JJ, Honig LS, Sanchez D, Reyes-Dumeyer D, Lantigua RA, et al. Plasma p-tau181, p-tau217, and other blood-based Alzheimer\u2019s disease biomarkers in a multi-ethnic, community study. Alzheimer\u2019s & Dementia. 2021; 17: 1353\u20131364.","DOI":"10.1002\/alz.12301"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Janelidze S, Palmqvist S, Leuzy A, Stomrud E, Verberk IMW, Zetterberg H, et al. Detecting amyloid positivity in early Alzheimer\u2019s disease using combinations of plasma A\u03b242\/A\u03b240 and p-tau. Alzheimer\u2019s & Dementia. 2022; 18: 283\u2013293.","DOI":"10.1002\/alz.12395"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Karikari TK, Benedet AL, Ashton NJ, Lantero Rodriguez J, Snellman A, Su\u00e1rez-Calvet M, et al. Diagnostic performance and prediction of clinical progression of plasma phospho-tau181 in the Alzheimer\u2019s Disease Neuroimaging Initiative. Molecular Psychiatry. 2021; 26: 429\u2013442.","DOI":"10.1038\/s41380-020-00923-z"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Ill\u00e1n-Gala I, Lleo A, Karydas A, Staffaroni AM, Zetterberg H, Sivasankaran R, et al. Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease. Neurology. 2021; 96: e671\u2013e683.","DOI":"10.1212\/WNL.0000000000011226"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Hall JR, Johnson LA, Peterson M, Julovich D, Como T, O\u2019Bryant SE. Relationship of Neurofilament Light (NfL) and Cognitive Performance in a Sample of Mexican Americans with Normal Cognition, Mild Cognitive Impairment and Dementia. Current Alzheimer Research. 2020; 17: 1214\u20131220.","DOI":"10.2174\/1567205018666210219105949"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Lewczuk P, Ermann N, Andreasson U, Schultheis C, Podhorna J, Spitzer P, et al. Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer\u2019s disease. Alzheimer\u2019s Research & Therapy. 2018; 10: 71.","DOI":"10.1186\/s13195-018-0404-9"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"Li J, Yuan X, Li H, Cao X, Yu J, Tan L, et al. Genome-wide association study identifies two loci influencing plasma neurofilament light levels. BMC Medical Genomics. 2018; 11: 47.","DOI":"10.1186\/s12920-018-0364-8"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Lin Y, Lee W, Wang S, Fuh J. Levels of plasma neurofilament light chain and cognitive function in patients with Alzheimer or Parkinson disease. Scientific Reports. 2018; 8: 17368.","DOI":"10.1038\/s41598-018-35766-w"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Liu S, Huang Z, Zhang L, Pan J, Lei Q, Meng Y, et al. Plasma Neurofilament Light Chain May Be a Biomarker for the Inverse Association Between Cancers and Neurodegenerative Diseases. Frontiers in Aging Neuroscience. 2020; 12: 10.","DOI":"10.3389\/fnagi.2020.00010"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Mattsson N, Andreasson U, Zetterberg H, Blennow K, Alzheimer\u2019s Disease Neuroimaging Initiative. Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurology. 2017; 74: 557\u2013566.","DOI":"10.1001\/jamaneurol.2016.6117"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"Osborn KE, Khan OA, Kresge HA, Bown CW, Liu D, Moore EE, et al. Cerebrospinal fluid and plasma neurofilament light relate to abnormal cognition. Alzheimer\u2019s & Dementia. 2019; 11: 700\u2013709.","DOI":"10.1016\/j.dadm.2019.08.008"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Palmqvist S, Janelidze S, Stomrud E, Zetterberg H, Karl J, Zink K, et al. Performance of Fully Automated Plasma Assays as Screening Tests for Alzheimer Disease-Related \u03b2-Amyloid Status. JAMA Neurology. 2019; 76: 1060\u20131069.","DOI":"10.1001\/jamaneurol.2019.1632"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Pereira JB, Westman E, Hansson O, Alzheimer\u2019s Disease Neuroimaging Initiative. Association between cerebrospinal fluid and plasma neurodegeneration biomarkers with brain atrophy in Alzheimer\u2019s disease. Neurobiology of Aging. 2017; 58: 14\u201329.","DOI":"10.1016\/j.neurobiolaging.2017.06.002"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Shi Y, Lu X, Zhang L, Shu H, Gu L, Wang Z, et al. Potential Value of Plasma Amyloid-\u03b2, Total Tau, and Neurofilament Light for Identification of Early Alzheimer\u2019s Disease. ACS Chemical Neuroscience. 2019; 10: 3479\u20133485.","DOI":"10.1021\/acschemneuro.9b00095"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Simr\u00e9n J, Leuzy A, Karikari TK, Hye A, Benedet AL, Lantero-Rodriguez J, et al. The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia. 2021; 17: 1145\u20131156.","DOI":"10.1002\/alz.12283"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Sugarman MA, Zetterberg H, Blennow K, Tripodis Y, McKee AC, Stein TD, et al. A longitudinal examination of plasma neurofilament light and total tau for the clinical detection and monitoring of Alzheimer\u2019s disease. Neurobiology of Aging. 2020; 94: 60\u201370.","DOI":"10.1016\/j.neurobiolaging.2020.05.011"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Walsh P, Sudre CH, Fiford CM, Ryan NS, Lashley T, Frost C, et al. The age-dependent associations of white matter hyperintensities and neurofilament light in early- and late-stage Alzheimer\u2019s disease. Neurobiology of Aging. 2021; 97: 10\u201317.","DOI":"10.1016\/j.neurobiolaging.2020.09.008"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Zhou W, Zhang J, Ye F, Xu G, Su H, Su Y, et al. Plasma neurofilament light chain levels in Alzheimer\u2019s disease. Neuroscience Letters. 2017; 650: 60\u201364.","DOI":"10.1016\/j.neulet.2017.04.027"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Chu WT, Wang W, Zaborszky L, Golde TE, DeKosky S, Duara R, et al. Association of Cognitive Impairment With Free Water in the Nucleus Basalis of Meynert and Locus Coeruleus to Transentorhinal Cortex Tract. Neurology. 2022; 98: e700\u2013e710.","DOI":"10.1212\/WNL.0000000000013206"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Jiao B, Liu H, Guo L, Liao X, Zhou Y, Weng L, et al. Performance of Plasma Amyloid \u03b2, Total Tau, and Neurofilament Light Chain in the Identification of Probable Alzheimer\u2019s Disease in South China. Frontiers in Aging Neuroscience. 2021; 13: 749649.","DOI":"10.3389\/fnagi.2021.749649"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Frank B, Ally M, Brekke B, Zetterberg H, Blennow K, Sugarman MA, et al. Plasma p-tau_\u2062181 shows stronger network association to Alzheimer\u2019s disease dementia than neurofilament light and total tau. Alzheimer\u2019s & Dementia. 2022; 18: 1523\u20131536.","DOI":"10.1002\/alz.12508"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Alcolea D, Delaby C, Mu\u00f1oz L, Torres S, Estell\u00e9s T, Zhu N, et al. Use of plasma biomarkers for AT(N) classification of neurodegenerative dementias. Journal of Neurology, Neurosurgery, and Psychiatry. 2021; 92: 1206\u20131214.","DOI":"10.1136\/jnnp-2021-326603"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Leuzy A, Mattsson-Carlgren N, Palmqvist S, Janelidze S, Dage JL, Hansson O. Blood-based biomarkers for Alzheimer\u2019s disease. EMBO Molecular Medicine. 2022; 14: e14408.","DOI":"10.15252\/emmm.202114408"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Liu S, Zhang Z, Shi S, Meng Y, Zhang X, Lei Q, et al. NREM sleep loss increases neurofilament light chain levels in APP\/PS1 and C57BL\/6 J mice. Sleep & Breathing. 2022. (online ahead of print)","DOI":"10.1007\/s11325-022-02719-7"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"Moscoso A, Grothe MJ, Ashton NJ, Karikari TK, Lantero Rodr\u00edguez J, Snellman A, et al. Longitudinal Associations of Blood Phosphorylated Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA Neurology. 2021; 78: 396\u2013406.","DOI":"10.1001\/jamaneurol.2020.4986"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"Chatterjee P, Pedrini S, Ashton NJ, Tegg M, Goozee K, Singh AK, et al. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer\u2019s disease. Alzheimer\u2019s & Dementia: the Journal of the Alzheimer\u2019s Association. 2022; 18: 1141\u20131154.","DOI":"10.1002\/alz.12447"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"Dittrich A, Ashton NJ, Zetterberg H, Blennow K, Simr\u00e9n J, Geiger F, et al. Plasma and CSF NfL are differentially associated with biomarker evidence of neurodegeneration in a community-based sample of 70-year-olds. Alzheimer\u2019s & Dementia. 2022; 14: e12295.","DOI":"10.1002\/dad2.12295"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"Parvizi T, K\u00f6nig T, Wurm R, Silvaieh S, Altmann P, Klotz S, et al. Real-world applicability of glial fibrillary acidic protein and neurofilament light chain in Alzheimer\u2019s disease. Frontiers in Aging Neuroscience. 2022; 14: 887498.","DOI":"10.3389\/fnagi.2022.887498"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"Teipel SJ, Stahl R, Dietrich O, Schoenberg SO, Perneczky R, Bokde ALW, et al. Multivariate network analysis of fiber tract integrity in Alzheimer\u2019s disease. NeuroImage. 2007; 34: 985\u2013995.","DOI":"10.1016\/j.neuroimage.2006.07.047"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"Zetterberg H, Skillb\u00e4ck T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM, et al. Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression. JAMA Neurology. 2016; 73: 60\u201367.","DOI":"10.1001\/jamaneurol.2015.3037"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"Chen Y, Therriault J, Luo J, Ba M, Zhang H, Initiative ADN. Neurofilament light as a biomarker of axonal degeneration in patients with mild cognitive impairment and Alzheimer\u2019s disease. Journal of Integrative Neuroscience. 2021; 20: 861\u2013870.","DOI":"10.31083\/j.jin2004088"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"Koychev I, Jansen K, Dette A, Shi L, Holling H. Blood-Based ATN Biomarkers of Alzheimer\u2019s Disease: A Meta-Analysis. Journal of Alzheimer\u2019s Disease. 2021; 79: 177\u2013195.","DOI":"10.3233\/JAD-200900"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"Zhang J, Cheng H, Liu W, Li H, Song Y, Jia L. Neurofilament light chain in cerebrospinal fluid or blood as a biomarker for mild cognitive impairment: A systematic review and meta-analysis. Medicine. 2022; 101: e28932.","DOI":"10.1097\/MD.0000000000028932"}],"container-title":["Journal of Integrative Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/22\/4\/10.31083\/j.jin2204085","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,27]],"date-time":"2024-11-27T11:00:00Z","timestamp":1732705200000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/JIN\/22\/4\/10.31083\/j.jin2204085"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,30]]},"references-count":54,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"alternative-id":["S0219-6352(23)00511-9"],"URL":"https:\/\/doi.org\/10.31083\/j.jin2204085","relation":{},"ISSN":["0219-6352","1757-448X"],"issn-type":[{"value":"0219-6352","type":"print"},{"value":"1757-448X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,30]]},"article-number":"85"}}